LNA-ANTIMIR
DEAD

Serial Number

79114443

Owner

Santaris Pharma A/S

Filing Date

Jan 4, 2012

Add to watchlist:

No watchlists yet
View on USPTO

LNA-ANTIMIR Trademark

Serial Number: 79114443

LNA-ANTIMIR is a trademark filed by Santaris Pharma A/S on January 4, 2012. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Santaris Pharma A/S (4 trademarks)

Kogle Alle 6
2970 Hørsholm , DK

Entity Type: 03

Trademark Details

Filing Date

January 4, 2012

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for the treatment of infectious diseases, metabolic disorders, inflammatory diseases, cardiovascular diseases, gastro-intestinal diseases, diseases of the central nervous system, autoimmune diseases, genetic disorders and malignant diseases; chemical preparations for pharmaceutical, medical and therapeutic purposes, namely, for the treatment of infectious diseases, metabolic disorders, inflammatory diseases, cardiovascular diseases, diseases of the central nervous system autoimmune diseases, genetic disorders and malignant diseases

Chemicals for use in industry and science; active chemical ingredients for use in the manufacture of pharmaceuticals or pharmaceutical development candidates for treating infectious diseases, metabolic disorders, inflammatory diseases, cardiovascular diseases, gastro-intestinal diseases, diseases of the central nervous system, autoimmune diseases, genetic disorders and malignant diseases; chemicals for use in the manufacture of medical and scientific preparations; nucleotides, nucleotide analogues and oligonucleotides for medical research and development

Scientific and technological services, namely, biopharmaceutical research as well as research and design connected thereto, namely, design and development of pharmaceutical products, biomedical and biotechnological analysis and research; development of medical and biomedical products and preparations; biochemical and molecular biological analysis; scientific, biotechnological and biomedical consultancy; in vivo and in vitro pre-clinical testing of potential pharmaceutical, medical preparations, methods and products

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Aug 1, 2022 DENA
DEATH OF INTERNATIONAL REGISTRATION
Jul 31, 2022 DETH
NEW REPRESENTATIVE AT IB RECEIVED
Nov 7, 2014 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 13, 2014 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Feb 24, 2014 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 22, 2014 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 11, 2014 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 26, 2013 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 25, 2013 OPNR
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Feb 22, 2013 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Feb 22, 2013 ABN2
REFUSAL PROCESSED BY IB
Aug 17, 2012 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 27, 2012 RFCS
REFUSAL PROCESSED BY MPU
Jul 27, 2012 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 27, 2012 RFCR
APPLICATION FILING RECEIPT MAILED
Jul 27, 2012 MAFR
NON-FINAL ACTION WRITTEN
Jul 26, 2012 CNRT
ASSIGNED TO EXAMINER
Jul 23, 2012 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 23, 2012 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jul 20, 2012 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 19, 2012 REPR